Dwight Evans is not exactly dominating the news cycle right now. The most recent social mentions of his name on Bluesky are baseball card rips and a stray post about how someone started writing about Billy Williams and ended up writing about Evans instead. Three posts total. The congressman from Philadelphia's 3rd district is, by the metrics, a quiet week. What is not quiet is his disclosure record, which shows five stock sales in the last 90 days, an 0-for-8 alpha record across his full scored sample, and one trade that touches his own committee's jurisdiction. The public record is sitting there. We read it so you don't have to.
Five Sales, One Spring, Zero Beats
Between May 7 and June 10, 2026, Evans disclosed five separate stock sales, all in the $1,000-to-$15,000 range. On May 7 alone, he filed three: Intel (INTC), Quanta Services (PWR), and Thermo Fisher Scientific (TMO). Then came American Tower (AMT) on May 11. Then General Dynamics (GD) on June 10.
None of these positions were large. The ceiling on each disclosure bracket is $15,000, meaning we're talking about the kind of portfolio activity that, in another context, a financial advisor would describe as "tidying up." The amounts are almost beside the point. The timing, and what the market did afterward, is the thing.
Across Evans's full scored sample of eight trades, zero came out ahead of the S&P 500 on a 30-day basis. Zero. The mean 30-day alpha across the sample is negative 5.7 percentage points. His best trade, the AMT sale on May 11, posted alpha of essentially flat: 0.0%. Everything else underperformed. His worst three: Quanta Services lost him 7.7 percentage points of relative performance, Thermo Fisher 7.8 points, and a March 24 sale of Micron Technology (MU) at $15,000-$50,000 came in at negative 14.1 points versus the index.
To be clear about what that means: selling a stock and then watching it beat the market afterward is, by itself, not a scandal. It happens. Markets are hard. But 0 positive outcomes out of 8 scored trades is a stat line that earns a second look, even if the second look mostly produces a shrug.
The One Trade That Has a Committee Angle
Evans sits on the House Committee on Ways and Means, including its Health and Work and Welfare subcommittees. Ways and Means has jurisdiction over tax policy, Medicare, Medicaid, Social Security, and trade. Healthcare, in other words, is squarely in his committee's lane.
The Thermo Fisher sale on May 7 carries a committee overlap flag. Thermo Fisher Scientific is a life sciences and laboratory equipment company that derives significant revenue from healthcare and pharmaceutical supply chains, territory that runs close to what Ways and Means Health oversees. Evans sold somewhere between $1,000 and $15,000 worth of TMO on May 7. The 30-day alpha on that trade came in at negative 7.8%: meaning the stock outperformed the S&P 500 in the month after he sold it.
There are no flagged vote-trade overlaps in this data set. The committee overlap designation on TMO is a jurisdictional observation, not a claim about Evans's intent or knowledge. Members sell stocks. Sometimes those stocks are in sectors their committees oversee. The disclosure system exists precisely so the public can see when that happens.
Members are required to disclose. They are not required to divest, recuse, abstain, blush, or look up from their phones.
What Evans Has Been Voting On
Evans's recent voting record is heavy on financial-services and banking legislation, which is worth noting given his portfolio activity, even though Ways and Means doesn't have jurisdiction over bank regulation. Floor votes are floor votes; they don't create the same oversight angle a committee assignment does.
On May 20, he voted Yea on three bills in the same session: the American Access to Banking Act (H.R. 4544), the Keeping Deposits Local Act (H.R. 3234), and the 25th Anniversary of 9/11 Commemorative Coin Act (H.R. 1993), all of which passed. On June 25, he voted Yea on the Financial Exploitation Prevention Act of 2025 (H.R. 2478), which also passed. On June 29, he voted Yea on the TRIA Program Reauthorization Act of 2026 (H.R. 7128), a bill reauthorizing the federal terrorism risk insurance backstop that touches the insurance sector directly.
The TRIA vote is the most market-relevant of the recent batch: terrorism risk insurance affects real estate investment trusts, large commercial property insurers, and financial institutions that require coverage as a lending condition. Evans voted to pass it. He didn't hold any disclosed positions in the insurance sector that would have created an obvious overlap. The voting record and the portfolio activity run largely on parallel tracks here.
He also voted Nay on June 11 on H.R. 9238, the FISA reauthorization bill, which failed. And Nay on May 21 on the Veterans 2nd Amendment Protection Act, which passed without him.
The General Dynamics Sale and What's Around It
The most recent trade in the 90-day window is the General Dynamics (GD) sale on June 10, 2026. General Dynamics is a defense contractor: Gulfstream jets, Abrams tanks, nuclear submarines, the whole portfolio. It has no obvious connection to Ways and Means jurisdiction and there's no flagged vote-trade overlap on the GD sale.
What makes it mildly worth mentioning is the company itself. Defense stocks have had a volatile 2026, and General Dynamics specifically has moved on news cycles tied to Pentagon budget negotiations and international arms sales. Evans sold at the low end of a $1,000-$15,000 bracket, so we're not talking about a position that would materially affect anyone's finances. The trade was disclosed. That's the system working as designed.
The Intel sale on May 7 is similar in texture. Intel has spent the better part of two years as one of the more troubled large-cap tech names, and the May 7 sale, while it underperformed the index by only 1.5 points over the following 30 days, is part of a cluster of three same-day sales that collectively lost ground against the market.
The Alpha Record in Plain English
Blind Trust scores disclosed trades against the S&P 500 on a 30-day forward basis. Evans's full scored sample runs to eight trades. The record: 0 positive, 8 negative, mean alpha of negative 5.7%.
His "best" trade, if you want to call it that, is the AMT sale on May 11, which came in at 0.0% alpha: a coin flip that landed on the rim. His second-best is the Intel sale at negative 1.5%. Then Apollo Global Management (APO), sold November 21, 2025, at negative 2.3%. The score gets worse from there, bottoming out at that Micron sale in March at negative 14.1 points.
To be honest about what this record does and doesn't mean: eight trades is a small sample. Market timing is hard for everyone, and the STOCK Act disclosure system catches trades after the fact, not in real time. An 0-for-8 record could reflect a genuinely unlucky stretch in a market that has rewarded staying put over active selling. It could also reflect something else. The data doesn't say which.
What the data does say is that every single scored trade Evans made in this sample lost ground to the index over the following month. That's the full record.
The Quiet Part
Evans is not a household name in the congressional trading conversation. He's not in the same sentence as the members whose portfolios generate weekly coverage. He's a Ways and Means Democrat from a safe Philadelphia district, and his trading activity is small-dollar and relatively infrequent.
But the structure of the public record still asks the same questions it always asks. He sits on a committee with healthcare jurisdiction. He sold a healthcare-adjacent stock. The stock outperformed the market after he sold it. The trade was disclosed on schedule. All of this is public.
The receipts are public. Make of them what you make of them.